Skip to content
sellModerate cluster of 4

Robert Leasure Jr. sold $281k of NOTV

President and CEO at Inotiv, Inc.. 73,617 shares at an average of $3.82, traded Feb 18, 2025, filed Feb 20, 2025.

Warning score
54
Value
$281k
73,617 shares
Holdings after
956,592
-7% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    CEO
    +25
  • Trade size
    $281k at market
    +14
  • Share of holdings sold
    Sold 7.1% of holdings
    0
  • Cluster
    4 insiders selling within 14 days
    +15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0001062993-25-003058, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Feb 18, 2025SOpen-market sale
Common Stock
-73,617$3.82$281k956,592Feb 20, 2025

Related signals

Other insiders at Inotiv, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
17Weak
NOTVsell 310b5-1
Inotiv, Inc.
Beth A. Taylor
Chief Financial Officer
$846
2,888 shares
-2%
10Weak
NOTVsell 310b5-1
Inotiv, Inc.
John E Sagartz
Chief Strategy Officer
$616
2,119 shares
-0%
20Weak
NOTVsell 310b5-1
Inotiv, Inc.
Robert Leasure Jr.
President and CEO
$4,964
16,810 shares
-1%
32Weak
NOTVsell
Inotiv, Inc.
Robert Leasure Jr.
President and CEO
$57k
113,297 shares
-8%
0Weak
NOTVsell10b5-1
Inotiv, Inc.
R Matthew Neff
director
$1,771
2,000 shares
-1%
0Weak
NOTVsell10b5-1
Inotiv, Inc.
R Matthew Neff
director
$2,487
2,000 shares
-1%
0Weak
NOTVsell10b5-1
Inotiv, Inc.
R Matthew Neff
director
$2,858
2,000 shares
-1%
0Weak
NOTVsell10b5-1
Inotiv, Inc.
R Matthew Neff
director
$3,338
2,000 shares
-1%
0Weak
NOTVsell10b5-1
Inotiv, Inc.
R Matthew Neff
director
$3,818
2,000 shares
-1%
0Weak
NOTVsell10b5-1
Inotiv, Inc.
R Matthew Neff
director
$3,621
2,000 shares
-1%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.